Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 3/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 3/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25544858 | 1.00 | PGR (0.42) | PGRTNKSMMP3KIF11MAP4K4 | |
| SCHEMBL25544849 | 0.93 | IDO1 (0.38) | PGRTNKSIDO1CYP3A4 | |
| SCHEMBL25544984 | 0.93 | IDO1 (0.38) | PGRTNKSIDO1CYP3A4 | |
| SCHEMBL25544993 | 0.93 | PGR (0.37) | PGRTNKSMMP3KIF11MAP4K4 | |
| SCHEMBL26289024 | 0.93 | PGR (0.37) | PGRTNKSMMP3KIF11MAP4K4 | |
| SCHEMBL25544996 | 0.90 | PGR (0.35) | PGRTNKSIDO1CYP3A4MAPT | |
| SCHEMBL25544861 | 0.89 | PGR (0.35) | PGRTNKSHRH3IDO1MAPT | |
| SCHEMBL25544841 | 0.89 | IDO1 (0.37) | PGRTNKSIDO1CYP3A4MAPT | |
| SCHEMBL17936235 | 0.84 | TNKS (0.41) | PGRTNKSMMP3CYP3A4MAPT | |
| SCHEMBL14295624 | 0.82 | TNKS (0.48) | PGRTNKSMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230301181-A1 | TERTIARY AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | LAPTO CO., LTD. (KR) | 2023-09-21 | — | — | US | disclosed |
| EP-4183784-A1 | TERTIARY AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | Lapto Co., Ltd. (KR) | 2023-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230301181-A1 | TERTIARY AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | SAT1, FTO, SETDB1 | PGR 3943/4885TNKS 617/4885MMP3 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.